Compare Alphabet Inc Class A (GOOGL) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alphabet Inc Class A vs Johnson & Johnson — how do they compare? Alphabet Inc Class A trades at $351.67 (market cap $4.24T), while Johnson & Johnson trades at $256.5 (market cap $618.09B). The key difference: Alphabet Inc Class A is far larger — about 6.9× Johnson & Johnson's market cap, and Johnson & Johnson pays the higher dividend (2.09%). Which is the better fit depends on your goals — on Pluang, investors hold Alphabet Inc Class A for 85 Days and Johnson & Johnson for 129 Days on average.
| GOOGL | JNJ | |
|---|---|---|
Market Cap | $4.24T | $618.09B |
Volume | 23,392,850 | 6,050,983 |
Sector | Media | Health |
52-Week High | $402.62 | $278.43 |
52-Week Low | $236.59 | $186.00 |
Typical Hold Time | 85 Days | 129 Days |
Enterprise Value | $4.13T | $646.37B |
Dividend Yield | 0.25% | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Alphabet (GOOGL) trades at $353.47, up 0.85% with strong bullish momentum. The stock shows robust fundamentals with revenue growth from $350.0B in 2024 to $402.8B in 2025 and net income surging to $132.2B. Technical indicators signal bullish momentum with the current price above key support levels. Recent earnings beats and strong analyst consensus support continued upside potential.
Outlook remains positive with 87% analyst buy ratings and $431.83 price target representing 22% upside. Key risks include antitrust scrutiny and AI competition, but Alphabet's diversified revenue streams and strong cash flow position the company for sustained growth. The combination of technical strength and fundamental excellence suggests favorable risk-reward for investors.
Johnson & Johnson (JNJ) trades at $259.62, up 0.45% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 21.48% net margin and 25.74% ROE, though valuation ratios appear elevated with P/E at 29.75. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with 52.5% buy ratings.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and increasing debt-to-asset ratio (24.06% in 2025). Analyst consensus target of $286.53 suggests 10% upside potential, though technical resistance at $260 may limit near-term gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alphabet Inc Class A
Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.
Read more on GOOGL →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
